Advaccine Funding: $166M Raised, IPO (2023)

Advaccine funding overview

Advaccine is based in Suzhou, China. Advaccine has raised $166M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is an IPO announced in February 2023. The round record for Advaccine runs through 2023; nothing later has been disclosed. Investors on record include Goldstream Investment, Hony Capital, Wosheng Investment, Dunhong Capital Management, Red Horse Investment Group. 5 distinct backers are named across the disclosed rounds.

Advaccine at a glance

Total raised: $166M
Latest round: IPO
Latest round date: February 2023
Headquarters: Suzhou, China
Notable investors: Goldstream Investment, Hony Capital, Wosheng Investment, Dunhong Capital Management, Red Horse Investment Group

Frequently asked about Advaccine funding

How much has Advaccine raised?: Advaccine has raised $166M in total disclosed funding across the rounds on record.
Who has invested in Advaccine?: Goldstream Investment, Hony Capital, Wosheng Investment, Dunhong Capital Management, Red Horse Investment Group are named among the investors backing Advaccine.
What was the latest Advaccine funding round?: The most recent disclosed round is an IPO, announced in February 2023.
Where is Advaccine based?: Advaccine is based in Suzhou, China.
When did Advaccine last raise?: The last disclosed Advaccine round closed in February 2023 at IPO.

Totals shown for Advaccine aggregate every disclosed round on file. To see how that compares, browse the companies in Suzhou and the investors behind them below.

Advaccine Funding: $166M Raised, IPO (2023)

Advaccine funding overview

Advaccine at a glance

Frequently asked about Advaccine funding

Companies related to Advaccine (18)

Browse related funding lists (4)